10Neurodevelopmental Effects of Childhood Exposure to Heavy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Neurological and Neuroimaging Signs of Reversible Parkinsonism Associated with Manganese Exposure
[Downloaded free from http://www.neurologyindia.com on Thursday, March 13, 2014, IP: 202.177.173.189] || Click here to download free Android application for this journal Editorial Neurological and neuroimaging signs of reversible Parkinsonism associated with manganese exposure Basant K. Puri Department of Imaging, Hammersmith Hospital, London, UK Address for correspondence: Prof. Basant K. Puri, Department of Imaging, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. E-mail: [email protected] Received : 03-02-2014 Review completed : 03-02-2014 Accepted : 03-02-2014 In this month’s issue of Neurology India, Han The heavy metal manganese (atomic number 25, relative et al. present an unusual case entitled ‘Reversal atomic mass 54.938) lies in group 7 of the periodic table of pallidal magnetic resonance imaging (MRI) T1 and has a natural abundance in the earth’s crust that, hyperintensity in a welder presenting as reversible among the heavy metals, is second only to that of iron, parkinsonism’.[1] Parkinsonism is a syndrome of multiple with which it is roughly similar in terms of many of its different etiologies and among the toxic causes of physical and chemical properties (although manganese is parkinsonism are alcohol (ethanol) withdrawal, methanol, harder and more brittle but less refractory).[5] It has one of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrodine, inhalant the highest industrial uses of all metals, being important in abuse, metals (including manganese, iron and copper), the production of steel and batteries, in water -
Manganese Toxicity May Appear Slowly Over Months and Years
MANGANESE 11 2. RELEVANCE TO PUBLIC HEALTH 2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO MANGANESE IN THE UNITED STATES Manganese is a naturally occurring element and an essential nutrient. Comprising approximately 0.1% of the earth’s crust, it is the twelfth most abundant element and the fifth most abundant metal. Manganese does not exist in nature as an elemental form, but is found mainly as oxides, carbonates, and silicates in over 100 minerals with pyrolusite (manganese dioxide) as the most common naturally-occurring form. As an essential nutrient, several enzyme systems have been reported to interact with or depend on manganese for their catalytic or regulatory function. As such, manganese is required for the formation of healthy cartilage and bone and the urea cycle; it aids in the maintenance of mitochondria and the production of glucose. It also plays a key role in wound-healing. Manganese exists in both inorganic and organic forms. An essential ingredient in steel, inorganic manganese is also used in the production of dry-cell batteries, glass and fireworks, in chemical manufacturing, in the leather and textile industries and as a fertilizer. The inorganic pigment known as manganese violet (manganese ammonium pyrophosphate complex) has nearly ubiquitous use in cosmetics and is also found in certain paints. Organic forms of manganese are used as fungicides, fuel-oil additives, smoke inhibitors, an anti-knock additive in gasoline, and a medical imaging agent. The average manganese soil concentrations in the United States is 40–900 mg/kg; the primary natural source of the manganese is the erosion of crustal rock. -
Manganese and Its Compounds: Environmental Aspects
This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organization, or the World Health Organization. Concise International Chemical Assessment Document 63 MANGANESE AND ITS COMPOUNDS: ENVIRONMENTAL ASPECTS First draft prepared by Mr P.D. Howe, Mr H.M. Malcolm, and Dr S. Dobson, Centre for Ecology & Hydrology, Monks Wood, United Kingdom The layout and pagination of this pdf file are not identical to the document in print Corrigenda published by 12 April 2005 have been incorporated in this file Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organization, and the World Health Organization, and produced within the framework of the Inter-Organization Programme for the Sound Management of Chemicals. World Health Organization Geneva, 2004 The International Programme on Chemical Safety (IPCS), established in 1980, is a joint venture of the United Nations Environment Programme (UNEP), the International Labour Organization (ILO), and the World Health Organization (WHO). The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from expos ure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management -
Understanding Lead Uptake and Effects Across Species Lines: a Conservation Medicine Based Approach
UNDERSTANDING LEAD UPTAKE AND EFFECTS ACROSS SPECIES LINES: A CONSERVATION MEDICINE BASED APPROACH MARK A. POKRAS AND MICHELLE R. KNEELAND Center for Conservation Medicine, Tufts University Cummings School of Veterinary Medicine, 200 Westboro Rd., North Grafton, MA 01536, USA. E-mail: [email protected] ABSTRACT.—Conservation medicine examines the linkages among the health of people, animals and the environment. Few issues illustrate this approach better than an examination of lead (Pb) toxicity. We briefly review the current state of knowledge on the toxicity of lead and its effects on wildlife, humans, and domestic animals. Lead is cheap and there is a long tradition of its use. But the toxic effects of Pb have also been recognized for centuries. As a result, western societies have greatly reduced many traditional uses of Pb, including many paints, gasoline and solders because of threats to the health of humans and the environment. Legisla- tion in several countries has eliminated the use of lead shot for hunting waterfowl. Despite these advances, a great many Pb products continue to be readily available. Conservationists recognize that hunting, angling and shooting sports deposit thousands of tons of Pb into the environment each year. Because of our concerns for human health and over 100 years of focused research, we know the most about lead poisoning in people. Even today, our knowledge of the long-term sublethal effects of Pb on human health continues to grow dramatically. Our knowledge about lead poisoning in domestic animals is signifi- cantly less. For wild animals, our understanding of lead poisoning is roughly where our knowledge about humans was in the mid-1800s when Tanquerel Des Planches made his famous medical observations (Tan- querel Des Planches 1850). -
HISTORY of LEAD POISONING in the WORLD Dr. Herbert L. Needleman Introduction the Center for Disease Control Classified the Cause
HISTORY OF LEAD POISONING IN THE WORLD Dr. Herbert L. Needleman Introduction The Center for Disease Control classified the causes of disease and death as follows: 50 % due to unhealthy life styles 25 % due to environment 25% due to innate biology and 25% due to inadequate health care. Lead poisoning is an environmental disease, but it is also a disease of life style. Lead is one of the best-studied toxic substances, and as a result we know more about the adverse health effects of lead than virtually any other chemical. The health problems caused by lead have been well documented over a wide range of exposures on every continent. The advancements in technology have made it possible to research lead exposure down to very low levels approaching the limits of detection. We clearly know how it gets into the body and the harm it causes once it is ingested, and most importantly, how to prevent it! Using advanced technology, we can trace the evolution of lead into our environment and discover the health damage resulting from its exposure. Early History Lead is a normal constituent of the earth’s crust, with trace amounts found naturally in soil, plants, and water. If left undisturbed, lead is practically immobile. However, once mined and transformed into man-made products, which are dispersed throughout the environment, lead becomes highly toxic. Solely as a result of man’s actions, lead has become the most widely scattered toxic metal in the world. Unfortunately for people, lead has a long environmental persistence and never looses its toxic potential, if ingested. -
Child Neurology: Hereditary Spastic Paraplegia in Children S.T
RESIDENT & FELLOW SECTION Child Neurology: Section Editor Hereditary spastic paraplegia in children Mitchell S.V. Elkind, MD, MS S.T. de Bot, MD Because the medical literature on hereditary spastic clinical feature is progressive lower limb spasticity B.P.C. van de paraplegia (HSP) is dominated by descriptions of secondary to pyramidal tract dysfunction. HSP is Warrenburg, MD, adult case series, there is less emphasis on the genetic classified as pure if neurologic signs are limited to the PhD evaluation in suspected pediatric cases of HSP. The lower limbs (although urinary urgency and mild im- H.P.H. Kremer, differential diagnosis of progressive spastic paraplegia pairment of vibration perception in the distal lower MD, PhD strongly depends on the age at onset, as well as the ac- extremities may occur). In contrast, complicated M.A.A.P. Willemsen, companying clinical features, possible abnormalities on forms of HSP display additional neurologic and MRI abnormalities such as ataxia, more significant periph- MD, PhD MRI, and family history. In order to develop a rational eral neuropathy, mental retardation, or a thin corpus diagnostic strategy for pediatric HSP cases, we per- callosum. HSP may be inherited as an autosomal formed a literature search focusing on presenting signs Address correspondence and dominant, autosomal recessive, or X-linked disease. reprint requests to Dr. S.T. de and symptoms, age at onset, and genotype. We present Over 40 loci and nearly 20 genes have already been Bot, Radboud University a case of a young boy with a REEP1 (SPG31) mutation. Nijmegen Medical Centre, identified.1 Autosomal dominant transmission is ob- Department of Neurology, PO served in 70% to 80% of all cases and typically re- Box 9101, 6500 HB, Nijmegen, CASE REPORT A 4-year-old boy presented with 2 the Netherlands progressive walking difficulties from the time he sults in pure HSP. -
Approach to the Poisoned Patient
PED-1407 Chocolate to Crystal Methamphetamine to the Cinnamon Challenge - Emergency Approach to the Intoxicated Child BLS 08 / ALS 75 / 1.5 CEU Target Audience: All Pediatric and adolescent ingestions are common reasons for 911 dispatches and emergency department visits. With greater availability of medications and drugs, healthcare professionals need to stay sharp on current trends in medical toxicology. This lecture examines mind altering substances, initial prehospital approach to toxicology and stabilization for transport, poison control center resources, and ultimate emergency department and intensive care management. Pediatric Toxicology Dr. James Burhop Pediatric Emergency Medicine Children’s Hospital of the Kings Daughters Objectives • Epidemiology • History of Poisoning • Review initial assessment of the child with a possible ingestion • General management principles for toxic exposures • Case Based (12 common pediatric cases) • Emerging drugs of abuse • Cathinones, Synthetics, Salvia, Maxy/MCAT, 25I, Kratom Epidemiology • 55 Poison Centers serving 295 million people • 2.3 million exposures in 2011 – 39% are children younger than 3 years – 52% in children younger than 6 years • 1-800-222-1222 2011 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System Introduction • 95% decline in the number of pediatric poisoning deaths since 1960 – child resistant packaging – heightened parental awareness – more sophisticated interventions – poison control centers Epidemiology • Unintentional (1-2 -
Accelerating Research. Empowering Families
RESEARCH STRATEGY AND MISSION We aggressively pursue research to identify treatments and a cure for Rett syndrome. New Mecp2 female mouse model developed AMO receives FDA Orphan Drug Designation 2018 + BEYOND With your support, we can Neuren begins plans for trofinetide Phase 3 continue to blaze a trail in Rett syndrome research and family 2017 14 clinics designated empowerment to transform lives. as Rett Syndrome Clinical Research First multi-site, Centers of Excellence multi-country clinical Join us in our mission: trial begins: sarizotan • Make a donation 2015 • Coordinate a Fundraiser Clinical trial for • Participate in an Event trofinetide begins • Advocate for Rett syndrome NIH funding of the NHS begins Visit www.rettsyndrome.org or Drug screening Scout program begins call 1.800.719.8214 2014 First multi-site clinical trial Rettsyndrome.org is a 501(c)3 organization in RTT begins: NNZ-2566 (trofinetide) Accelerating dedicated to accelerating research for treatments and a cure for Rett syndrome and related disorders, 2013 while providing family empowerment. As a Established stem Research. leading organization for Rett syndrome research, cell model for Rettsyndrome.org is committed to funding high- drug screening First clinical trial quality, peer-reviewed research grants and programs. in RTT supported by Rettsyndrome.org: IGF-1 Empowering Genetic manipulation 2010 and biochemical Families. intervention improve Rett-like symptoms in a mouse model 2007 4600 Devitt Drive Cincinnati, OH 45246-1104 ‘‘ (800) 818-7388 www.rettsyndrome.org I am very thankful that Rettsyndrome.org has taken such a strong leadership role /rettsyndrome /rettsyndrome /rettsyndromeorg with advancing research. Their progress to get trofinetide to market is very exciting as it could finally be an answer to relieving some of Jill’s daily struggles. -
Hereditary Spastic Paraparesis: a Review of New Developments
J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region. -
Cerebral Palsy the ABC's of CP
Cerebral Palsy The ABC’s of CP Toni Benton, M.D. Continuum of Care Project UNM HSC School of Medicine April 20, 2006 Cerebral Palsy Outline I. Definition II. Incidence, Epidemiology and Distribution III. Etiology IV. Types V. Medical Management VI. Psychosocial Issues VII. Aging Cerebral Palsy-Definition Cerebral palsy is a symptom complex, (not a disease) that has multiple etiologies. CP is a disorder of tone, posture or movement due to a lesion in the developing brain. Lesion results in paralysis, weakness, incoordination or abnormal movement Not contagious, no cure. It is static, but it symptoms may change with maturation Cerebral Palsy Brain damage Occurs during developmental period Motor dysfunction Not Curable Non-progressive (static) Any regression or deterioration of motor or intellectual skills should prompt a search for a degenerative disease Therapy can help improve function Cerebral Palsy There are 2 major types of CP, depending on location of lesions: Pyramidal (Spastic) Extrapyramidal There is overlap of both symptoms and anatomic lesions. The pyramidal system carries the signal for muscle contraction. The extrapyramidal system provides regulatory influences on that contraction. Cerebral Palsy Types of brain damage Bleeding Brain malformation Trauma to brain Lack of oxygen Infection Toxins Unknown Epidemiology The overall prevalence of cerebral palsy ranges from 1.5 to 2.5 per 1000 live births. The overall prevalence of CP has remained stable since the 1960’s. Speculations that the increased survival of the VLBW preemies would cause a rise in the prevalence of CP have proven wrong. Likewise the expected decrease in CP as a result of C-section and fetal monitoring has not happened. -
Epilepsy and Cerebral Palsy*
Arch Dis Child: first published as 10.1136/adc.31.155.1 on 1 February 1956. Downloaded from EPILEPSY AND CEREBRAL PALSY* BY BRIAN H. KIRMAN From the Fountain Hospital, Tooting, London (RECEIVED FOR PUBLICATION SEPTEMBER 6, 1955) The two conditions epilepsy and palsy in its Frequency of Epilepsy as a Complication many forms are amongst the earliest syndromes of Cerebral Palsy recorded in history. The association between Brissaud and Souques (1904) attempted to confine epilepsy and cerebral palsy in childhood is a matter the term 'Little's disease' to those cases not com- of everyday experience, and this association is of plicated by fits or mental defect, but Little's (1861-2) scientific interest as throwing light on the nature of own description of 63 cases refers specifically to the cerebral palsy and, more particularly, of epilepsy. complication ofconvulsions. Kinnier Wilson (1940) It is also of practical importance in view of recent refers to Little's disease not as 'an ailment of a well efforts to make more adequate provision for those defined character but a mere syndrome and a rather children with cerebral palsy who are educable. wide-ranging one at that'. Since epilepsy is also The existence of the two conditions in one child not a disease but a symptom of cerebral dysfunction constitutes a double handicap. The present ten- it is understandable that cerebral palsy and epilepsy dency in our educational system is for ever-increasing should often be encountered in the same patient. copyright. subdivision of educational 'types', and any child Kinnier Wilson states that in his experience 30% of who is difficult to fit into one of the artificial cate- cases of cerebral diplegia have fits which may be gories thus constructed is in danger of remaining general or one-sided. -
Sound Management of Pesticides and Diagnosis and Treatment Of
* Revision of the“IPCS - Multilevel Course on the Safe Use of Pesticides and on the Diagnosis and Treatment of Presticide Poisoning, 1994” © World Health Organization 2006 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. CONTENTS Preface Acknowledgement Part I. Overview 1. Introduction 1.1 Background 1.2 Objectives 2. Overview of the resource tool 2.1 Moduledescription 2.2 Training levels 2.3 Visual aids 2.4 Informationsources 3. Using the resource tool 3.1 Introduction 3.2 Training trainers 3.2.1 Organizational aspects 3.2.2 Coordinator’s preparation 3.2.3 Selection of participants 3.2.4 Before training trainers 3.2.5 Specimen module 3.3 Trainers 3.3.1 Trainer preparation 3.3.2 Selection of participants 3.3.3 Organizational aspects 3.3.4 Before a course 4.